[Event-related potentials in moderate cognitive impairment in patients with chronic cerebral ischemia treated with cytoflavin].
Authors compared cognitive functions in 60 patients (main group) with different stages of discirculatory encephalopathy (DE), I, II and III stages. A comparison group included 10 age-matched normals without DE. All patients underwent a clinical-neurological investigation and performed neuropsychological tests (MMSE, the Clock drawing test, Burdon probe) and Spilberger-Khanin test. Cognitive evoked potentials, including P300, were recorded. Results revealed the decrease in performance on neuropsychological tests and P300 components that indicated the slowing of metabolic processes in the cerebral cells of patients with DE. In patients treated with cytoflavin, the activation of metabolic processes in the brain cells that indicated the protection of the cellular cluster clinically manifested itself in neurocognitive and electrophysiological improvements was observed.
Tashkentskiĭ meditsinskiĭ pediatricheskiĭ institut, Tashkent.
E N
EN
Madzhidova
D K
DK
Khaĭdarova
D T
DT
Khodzhaeva
D000161:Acoustic Stimulation; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003071:Cognition; D060825:Cognitive Dysfunction / Q000209:etiology / Q000503:physiopathology*; D004338:Drug Combinations; D005071:Evoked Potentials / Q000502:physiology*; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009536:Niacinamide / Q000627:therapeutic use*; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate